By Chris Wack
I-Mab shares were 13% higher, at $3.84, after the company said enrollment in its planned Phase 1b dose expansion cohorts evaluating givastomig in combination with nivolumab and mFOLFOX6 has been completed ahead of expectations.
The biotechnology company said the Phase 1b study is evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig, a potential best-in-class, bispecific antibody, used with nivolumab and mFOLFOX6, as first line therapy in patients with positive gastric cancers.
The primary endpoint is safety. The dose expansion cohorts of the study enrolled a total of 40 patients across two doses--8 mg/kg and 12 mg/kg-- and enrolled only patients in the U.S.
The stock hit its 52-week high of $4.18 on Thursday, and is up 260% in the past 12 months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
August 11, 2025 12:35 ET (16:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.